Shah, 465 patient antiandrogen prophylaxis study: 16% higher mortality [p=0.59], 19% lower ventilation [p=0.73], 3% higher severe cases [p=0.91], and 4% lower hospitalization [p=0.9] https://c19p.org/shah3
copied to clipboard
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
et al., JNCI Cancer Spectrum, doi:10.1093/jncics/pkac035
Retrospective 465 prostate cancer patients, showing no significant difference in COVID-19 outcomes with ADT.
|
risk of death, 16.0% higher, HR 1.16, p = 0.59, treatment 148, control 317.
|
|
risk of mechanical ventilation, 19.0% lower, HR 0.81, p = 0.73, treatment 148, control 317.
|
|
risk of severe case, 3.0% higher, HR 1.03, p = 0.91, treatment 148, control 317.
|
|
risk of hospitalization, 4.0% lower, HR 0.96, p = 0.90, treatment 148, control 317.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Shah et al., 5/12/2022, retrospective, USA, North America, peer-reviewed, median age 71.0, 22 authors, study period 1 March, 2020 - 31 May, 2020.
Contact:
william.oh@mssm.edu.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.